$MSCLF News

Last published 9mo ago

9mo agoMSCLF TSX:MSCLSatellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular DystrophyBusiness WireBASECAMP, a three-month, randomized, double-blind, placebo-controlled study, will evaluate SAT-3247's safety and tolerability, and effect on muscle force, muscle quality and muscle regeneration Satellos Bioscience
9mo agoMSCLF TSX:MSCLSatellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on NasdaqBusiness WireBASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+ Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage
9mo agoGBIO MSCLF TSX:MSCL VRTXSatellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory AffairsBusiness WireExperienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the
9mo agoMSCLF TSX:MSCLSatellos Announces Share Consolidation in Connection with Proposed Nasdaq ListingBusiness WireSatellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announces that the
11mo agoMSCLF TSX:MSCLSatellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular DystrophyBusiness Wire- Placebo-controlled Phase 2 study will evaluate SAT-3247 treatment over three months among ambulatory children with Duchenne - Study endpoints include safety and tolerability, effect on muscle force and function, and
11mo agoMSCLF TSX:MSCLSatellos to Participate in December Investor ConferencesBusiness WireSatellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it
11mo agoMSCLF TSX:MSCLSatellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular DystrophyBusiness WireResearch confirms muscle stem cell dysfunction impairs polarity and impedes production of myogenic progenitors during fetal development Findings solidify AAK1 as a paradigm shifting drug target to restore muscle
12mo agoMSCLF TSX:MSCLSatellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of DirectorsBusiness WireAppointed Mark Nawacki, seasoned M&A expert, co-founder, president & former CEO of Searchlight Pharma, to Board of Directors Completed IND submission to the U.S. FDA and global regulatory filings to advance
1y agoMSCLF TSX:MSCLSatellos to Participate in November Investor ConferencesBusiness WireSatellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that its
1y agoMSCLF TSX:MSCLSatellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular DystrophyBusiness WireFirst returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled 11-month open-label study will evaluate functional outcomes, safety, muscle composition by MRI, and
1y agoMSCLF TSX:MSCLSatellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular DystrophyBusiness WireAdults with Duchenne muscular dystrophy demonstrated functional improvements exceeding natural history, following 28-day treatment with SAT-3247 Grip strength increased 118.6% and predicted forced vital capacity
1y agoMSCLF TSX:MSCLSatellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society CongressBusiness WireSatellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it
1y agoMSCLF TSX:MSCLSatellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular DystrophyBusiness WireRegulatory submissions filed in the U.S., UK, Europe, Serbia and Australia Three-month randomized placebo-controlled study to assess safety, pharmacokinetics, dose, muscle biopsies, and measures of function in
1y agoMSCLF TSX:MSCLSatellos to Participate in Four September Institutional and Retail Investor ConferencesBusiness WireSatellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today that
1y agoMSCLF TSX:MSCLSatellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical MilestonesBusiness WireReported positive Phase 1b data in five adults with Duchenne muscular dystrophy (DMD) after 28 days of treatment Demonstrated safety, tolerability and an approximate doubling in grip strength On track to
1y agoMSCLF TSX:MSCLSatellos to Present at Canaccord Genuity's 45th Annual Growth ConferenceBusiness WireSatellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the
1y agoDYN MSCLF TSX:MSCLSatellos Appoints Dr. Wildon Farwell as Chief Medical OfficerBusiness WireBrings a successful track record in clinical development and regulatory approval of innovative neuromuscular therapies Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a biotech company
1y agoMSCLF TSX:MSCLSatellos Bioscience Announces Results of Annual and Special Meeting of ShareholdersBusiness WireSatellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced
1y agoMSCLF TSX:MSCLSatellos Bioscience Shareholders Elect Two New Board MembersBusiness WireSatellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today
1y agoMSCLF TSX:MSCLSatellos Bioscience to Participate in PPMD's Annual Conference in Las VegasBusiness WireSatellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today
1y agoMSCLF TSX:MSCLSatellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular DystrophyBusiness WirePhase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent
1y agoMSCLF TSX:MSCLSatellos Reports First Quarter 2025 Results and Highlights Recent Company ProgressBusiness Wire- Completed enrollment in the Phase 1b trial in adult patients with Duchenne muscular dystrophy (DMD); data analysis and reporting expected in Q2 2025 - Received regulatory approval, allowing initiation of a long-term
1y agoMSCLF TSX:MSCLSatellos to Present at the CureDuchenne FUTURES National ConferenceBusiness WireSatellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the
1y agoMSCLF TSX:MSCLSatellos to Present at Bloom Burton & Co. Healthcare Investor ConferenceBusiness WireSatellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the 2025
1y agoMSCLF TSX:MSCLSatellos to Participate in Two April Investor ConferencesBusiness WireSatellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present and
1y agoMSCLF TSX:MSCLSatellos Reports 2024 Financial Results and Highlights Company ProgressBusiness Wire– Completed enrollment and dosing in a Phase 1a clinical trial in 72 healthy volunteers to assess safety and pharmacokinetic (PK) properties of SAT-3247 – Presented initial Phase 1a data at Muscular Dystrophy
1y agoMSCLF TSX:MSCLSatellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific ConferenceBusiness Wire- Phase 1a data shows SAT-3247 was safe and well tolerated in 72 healthy volunteers after both single and repeated administration - Phase 1a data shows favorable pharmacokinetic (PK) profile of SAT-3247, reinforcing
1y agoMSCLF TSX:MSCLSatellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific ConferenceBusiness Wire- Satellos plans to highlight Phase 1 safety and PK data for SAT-3247 Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic
1y agoMSCLF TSX:MSCLSatellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy VolunteersBusiness Wire- Company remains on track to report Phase 1a data from both the Single- and Multiple-Ascending Dose (SAD and MAD) cohorts in the healthy volunteer portion of the study in 1Q 2025 at an upcoming major medical
1y agoMSCLF TSX:MSCLSatellos to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceBusiness WireSatellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders,
1y agoMSCLF TSX:MSCLSatellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247Business Wire- Marks successful completion of full enrollment of SAD cohorts and the first two MAD cohorts in the healthy volunteer study - Up to 10 adult participants with genetically confirmed Duchenne Muscular Dystrophy ("DMD")
1y agoMSCLF TSX:MSCLSatellos to Participate in Oppenheimer Movers in Rare Disease SummitBusiness WireSatellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today
1y agoABBV LXEO MSCLF TSX:MSCLSatellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024Business WireSatellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases
1y agoMSCLF TSX:MSCLSatellos Appoints Stephanie Brown to Board of DirectorsBusiness WireSatellos Bioscience Inc. (TSX:MSCL) (OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders,
1y agoMSCLF TSX:MSCLSatellos Reports Q3 2024 Financial Results and Provides Clinical UpdateBusiness Wire- Completed enrollment for SAT-3247 in Duchenne muscular dystrophy (DMD) in the first three (of five) single-ascending dose (SAD) cohorts with no safety concerns and initiated enrollment of first multiple-ascending-dose
2y agoMSCLF TSX:MSCLSatellos to Participate in November 2024 Investor ConferencesBusiness WireSatellos Bioscience Inc. ("Satellos" or the "Company") (TSX:MSCL) (OTCQB:MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders,
2y agoMSCLF TSX:MSCLSatellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal LevelsBusiness Wire- Analysis showed improvement in muscle morphology and increased levels of regeneration in muscle groups, including the diaphragm, quadriceps, and calf - No adverse events and no significant changes in hematology or
2y agoMSCLF TSX:MSCLSatellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247Business Wire- The first healthy volunteer has been dosed in the first component of the Phase 1 study - Initial safety and pharmacokinetic data expected in Q4 2024 - Initiation of the second component of the Phase 1 study, in
2y agoMSCLF TSX:MSCLSatellos Announces Participation in September 2024 Investor ConferencesBusiness WireSatellos Bioscience Inc. ("Satellos" or the "Company") (TSX:MSCL) (OTCQB:MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders,
2y agoMSCLF TSX:MSCLSatellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247Business WireDosing of first participant in a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. ("Satellos" or the "Company") (TSX:MSCL, OTCQB:MSCLF), a public biotech company developing new small
2y agoMSCLF TSX:MSCLSatellos Announces Q2 2024 Financial Results and Updated Canine DataBusiness Wire- Updated data in a canine model of Duchenne muscular dystrophy (DMD) show further increased improvement in muscle force over baseline of 195% at four-month point - Receipt of Orphan Drug and Rare Pediatric Disease
2y agoMSCLF TSX:MSCLSatellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular DystrophyBusiness Wire– SAT-3247 is a proprietary, oral small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle which is lost in Duchenne muscular dystrophy (DMD) – DMD is a rare genetic disorder
2y agoMSCLF TSX:MSCLSatellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247Business Wire– Investigational New Drug (IND) enabling preclinical and toxicology studies successfully completed – Initiation of a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. ("Satellos" or
2y agoMSCLF TSX:MSCLSatellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy ("DMD")Business Wire–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine model of DMD – Satellos remains on track to initiate a Phase 1
2y agoMSCLF TSX:MSCLSatellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual ConferenceBusiness Wire– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos Bioscience Inc. ("Satellos" or the "Company") (TSX:MSCL,
2y agoMSCLF TSX:MSCLSatellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular DystrophyBusiness WireSatellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel regenerative medicine approach to treating DMD Satellos Bioscience Inc.
2y agoMSCLF TSX:MSCLSatellos Bioscience Announces Results of Annual and Special Meeting of ShareholdersBusiness WireSatellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders,
2y agoMSCLF TSX:MSCLSatellos Bioscience Announces Q1 2024 Financial Results and Operational HighlightsBusiness Wire- Conducted preclinical toxicology studies and GMP manufacturing of SAT-3247 - On track to initiate Phase 1 first-in-human clinical trials mid-2024 - Cash balance of $33.2 million at March 31, 2024 - Invited to
2y agoMSCLF TSX:MSCLSatellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceBusiness WireSatellos Bioscience Inc. ("Satellos" or the "Company") (TSX:MSCL) (OTCQB:MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders,
2y agoMSCLF TSX:MSCLSatellos Bioscience Announces 2023 Year End Financial Results and Operational HighlightsBusiness Wire- Engaged CRO for first-in-human SAT-3247 Phase 1 clinical study - Initiated GLP toxicity studies and GMP manufacturing of SAT-3247 - Continues to be on track to initiate first-in-human clinical trials mid-2024 -